Optimi Health Secures Key Licence for Psychedelic Treatments

Optimi Health (TSE:OPTI) has released an update.

Optimi Health Corp. has received a Drug Establishment Licence from Health Canada, enabling the company to manufacture and sell GMP-compliant MDMA and psilocybin capsules for patients with PTSD and Treatment-Resistant Depression in Australia and potentially worldwide. This significant achievement allows Optimi to begin the process of registering the drugs with the U.S. FDA and to supply initial doses to fulfill prescriptions through Mind Medicine Australia. The licence positions Optimi as a key player in the burgeoning global psychedelics market, with a fully operational infrastructure to commercialize their pharmaceutical-grade products.

For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.